Continued participation in NCI-funded research through NCTN program as a LAPS site is in alignment with the missions of the Duke School of Medicine and the DCI. The DCI faculty are heavily focused on translation of discovery to the clinic and from the clinic to the community. The NCTN program has provided structure for our faculty to bring scientific discovery from Duke to clinical research being conducted on a national level and at the same time gives us an opportunity to participate in and/or lead a portfolio of clinical studies designed to improve cancer therapy for our patients through better diagnostics, imaging, and targeted therapies. Duke has a long- standing history of NCI sponsored clinical trial research and we also maintain active memberships in all 4 Adult networks, including positions of leadership in Alliance, ECOG-ACRIN, NRG and SWOG. The DCI infrastructure support, along with our long-standing participation as an institution in cooperative group/NCTN activities, clearly demonstrates our continued commitment to NCI- funded clinical research. Duke Faculty have contributed substantially to the scientific leadership of NCTN Network Groups and NCI initiatives. Since the inception of the NCTN over the last 2 grant cycles, Duke faculty have filled more than 140 NCTN committee positions, including 2 chairs, 4 imaging chairs, 3 co- chairs, and 4 vice-chair positions. Duke Faculty have demonstrated active participation that has led to more than X publications since 2019. Duke investigators have also served as study chairs or co-chairs for X trials over since Mar 2019.[AT1] [JR2]

PROJECT NARRATIVE Participation of patients and investigators in National Clinical Trials Network (NCTN) clinical trials is vital to our understanding of the biology and treatment of cancer. Support of NCTN leadership activities of Duke faculty and clinical research staff effort will help us maintain our high patient enrollment and robust scientific participation in clinical trials of national importance.